Use of enfortumab vedotin in an HIV-positive patient with urothelial carcinoma

Introduction Enfortumab vedotin is an antibody-drug conjugate used in patients with pretreated advanced urothelial carcinoma. Patients with human immunodeficiency virus were excluded from clinical trials conducted with this agent. Efficacy and safety of enfortumab vedotin has not been established in...

Full description

Saved in:
Bibliographic Details
Published in:Journal of oncology pharmacy practice 2022-07, Vol.28 (5), p.1226-1229
Main Authors: Azizi, Armon, Houshyar, Roozbeh, Mar, Nataliya
Format: Article
Language:English
Subjects:
Antibodies, Monoclonal - adverse effects
Antiretroviral drugs
Antiretroviral therapy
Bladder cancer
Cancer
Carcinoma, Transitional Cell - drug therapy
Chemotherapy
Clinical trials
Drug therapy
HIV
Human immunodeficiency virus
Humans
Immune system
Immunoconjugates - therapeutic use
Male
Metastases
Patients
Pembrolizumab
Toxicity
Urinary Bladder Neoplasms - drug therapy
Urothelial carcinoma
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction Enfortumab vedotin is an antibody-drug conjugate used in patients with pretreated advanced urothelial carcinoma. Patients with human immunodeficiency virus were excluded from clinical trials conducted with this agent. Efficacy and safety of enfortumab vedotin has not been established in this patient population. Case report A patient with a long-standing diagnosis of human immunodeficiency virus and an undetectable viral load on antiretroviral therapy was diagnosed with metastatic upper tract urothelial carcinoma. Following disease progression on platinum-based chemotherapy and pembrolizumab, he was initiated on therapy with enfortumab vedotin. Management & outcome The patient developed significant toxicity shortly after initiation of enfortumab vedotin. His treatment was subsequently changed to docetaxel chemotherapy and he developed similar significant toxicity. Upon changing his antiretroviral therapy regimen, he was rechallenged with enfortumab vedotin and was able to tolerate it without dose-limiting toxicity, ultimately achieving a partial treatment response. Discussion This case describes use of enfortumab vedotin in a patient with human immunodeficiency virus, which has not previously been reported. It also underscores the importance of careful medication reconciliation in patients receiving enfortumab vedotin and antiretroviral therapy.
ISSN:1078-1552
1477-092X
DOI:10.1177/10781552221074309